Track larazotide in Peptimes™
Larazotide is a synthetic peptide of 8 amino acids: Gly-Gly-Val-Leu-Val-Gln-Pro-Gly. FDA's substance registry lists its acetate salt, larazotide acetate, also as AT-1001. (Source: FDA's substance registry (GSRS).)
Is larazotide FDA-approved?
No. Larazotide isn't FDA-approved, and Drugs@FDA lists no application with it as an active ingredient.
Larazotide
Also: larazotide acetate, AT-1001, INN-202, Gly-Gly-Val-Leu-Val-Gln-Pro-Gly
- Status label in the Peptimes Library
- Not FDA-Approved
- Routes in Peptimes
- Oral
- Updated
- 1 Nov 2026
US regulatory status
What studies have looked at
Each point says who or what was studied and what the study reported, with its source and the date we checked it. These are findings from the sources cited, not advice or a promise of any result.
- Review of studies
A 2022 meta-analysis of 4 randomized trials in 626 people with celiac disease: larazotide improved gastrointestinal symptom scores compared with placebo in people given a gluten challenge, but not in people on a gluten-free diet alone. It didn't change a gut permeability test.
Source: PMID 34339872, checked 1 Nov 2026
How to track it in Peptimes
Add larazotide in My Protocols and set the schedule you already follow: days of the week, times of day and a start date. Peptimes never suggests an amount when you log or schedule a dose. Its Library entry shows the status label “Not FDA-Approved”.
- Logging: the amount you took and how you feel. It’s logged as oral, so there’s no injection site to record.
- Reminders and history: reminders at your times, Dose History, the Calendar and CSV or JSON export work as described on the peptide tracker app page.
Peptimes is a tracking app, not medical advice. Talk to a licensed clinician about your treatment. Peptimes doesn’t sell larazotide or any other compound.
More sources
- FDA, Global Substance Registration System, Larazotide and Larazotide acetate, checked 1 Nov 2026: its sequence of 8 amino acids, and the code name AT-1001.
- FDA, Drugs@FDA, checked 1 Nov 2026 through FDA’s openFDA Drugs@FDA data: no application lists larazotide as an active ingredient.
- ClinicalTrials.gov, search “larazotide”, checked 1 Nov 2026: its registered trials are completed or terminated.